Improving Outcomes in Metastatic HER2+ Breast Cancer: Translating Evidence to Clinical Practice : Episode 7

Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

Jun 5, 2023

Virginia G. Kaklamani, MD, DSc

Video

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

EP: 1.Landscape of HER2+ Metastatic Breast Cancer: Patient Overview

EP: 2.HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium

EP: 3.HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond

EP: 4.Role of T-DXd in Patients With HER2+ Metastatic Breast Cancer and CNS Metastasis

EP: 5.HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care

EP: 6.Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

EP: 7.Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

EP: 8.Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer

EP: 9.Role of Brain Metastases and Quality of Life in Treatment Decisionmaking

EP: 10.Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

EP: 11.HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

Related Videos

Experts on GVHD

Judy C. Boughey, MD

Francisco J. Esteva, MD, PhD

Experts on FL

Expert on FL

Expert on SCLC

Experts on myelodysplastic syndrome

Experts on myelodysplastic syndrome

Stephanie L. Graff, MD

Related Content

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Continued Research Underscores the Need to Explore New Approaches Across the Breast Cancer Armamentarium

September 15th 2023

State of the Science Summit - Breast: Chaired by Paul Lawrence Baron, MD

September 11th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Continued Research Underscores the Need to Explore New Approaches Across the Breast Cancer Armamentarium

September 15th 2023

State of the Science Summit - Breast: Chaired by Paul Lawrence Baron, MD

September 11th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Continued Research Underscores the Need to Explore New Approaches Across the Breast Cancer Armamentarium

September 15th 2023

State of the Science Summit - Breast: Chaired by Paul Lawrence Baron, MD

September 11th 2023

Related Content

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Francois-Clement Bidard, MD, PhD

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Elcin Barker Ergun

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Patrick I. Borgen, MD; Laura J. Esserman, MD, MBA; Kelly K. Hunt, MD, FACS, FSSO; Kevin Kalinsky, MD, MS; Lisa A. Carey MD, ScM, FASCO, Steven J. Chmura, MD, PhD

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Stephanie L. Graff, MD

Continued Research Underscores the Need to Explore New Approaches Across the Breast Cancer Armamentarium

September 15th 2023

State of the Science Summit - Breast: Chaired by Paul Lawrence Baron, MD

State of the Science Summit - Breast: Chaired by Paul Lawrence Baron, MD

September 11th 2023

Latest Conference Coverage

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.